Chronic Kidney Diseases Clinical Trial
— TRANQUILITYOfficial title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Quarterly and Monthly TOUR006 in Participants With Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein
This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 in participants with chronic kidney disease and elevated hs-CRP.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | February 2026 |
Est. primary completion date | May 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age =18 years at time of ICF signature. - Serum hs-CRP level =2.0 mg/L and <15 mg/L - Diagnosis of chronic kidney disease, eGFR =15 and <60 mL/min/1.73 m2 - Received COVID-19 vaccine at least 30 days prior to the Screening visit, per participant verbal attestation. - Agreement to comply with contraception and reproduction restrictions Exclusion Criteria: - Clinical evidence or suspicion of active infection - Current or recent COVID-19 infection within 30 days - Serious infection within 12 months - Any history of a serious opportunistic infection - Known history of immunodeficiency - History of gastrointestinal ulceration or perforation - History of active diverticulitis, active inflammatory bowel disease, or GI abscess within 12 months - History of GI bleeding requiring hospitalization and/or transfusion within 6 months - New York Heart Association Class III or IV congestive heart failure and/or hospitalization for heart failure exacerbation within 6 months - Acute coronary syndrome, stroke, transient ischemic attack, or other thrombotic or thromboembolic event, or arterial revascularization procedure within 6 months |
Country | Name | City | State |
---|---|---|---|
United States | Site - 0101 | Birmingham | Alabama |
United States | Site - 0110 | Charlotte | North Carolina |
United States | Site - 0117 | Fargo | North Dakota |
United States | Site - 0102 | Fort Mill | South Carolina |
United States | Site - 0103 | Greenville | South Carolina |
United States | Site - 0105 | Houston | Texas |
United States | Site - 0108 | Knoxville | Tennessee |
United States | Site - 0111 | Lampasas | Texas |
United States | Site - 0123 | Las Vegas | Nevada |
United States | Site - 0109 | Manassas | Virginia |
United States | Site - 0127 | Marion | Ohio |
United States | Site - 0104 | Phoenix | Arizona |
United States | Site - 0116 | Rapid City | South Dakota |
United States | Site - 0107 | San Antonio | Texas |
United States | Site - 0125 | San Dimas | California |
United States | Site - 0121 | Wauwatosa | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
Tourmaline Bio, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate the effects of TOUR006 compared with placebo on hs-CRP | Evaluates the change from baseline in hs-CRP comparing TOUR006 and placebo | 90 days | |
Secondary | Evaluate the effects of TOUR006 compared with placebo on hs-CRP | Evaluates the change from baseline in hs-CRP comparing TOUR006 and placebo | 180 days | |
Secondary | Evaluate the pharmacokinetics by measuring serum concentrations of TOUR006 | Evaluates the serum concentrations of TOUR006 over time | Baseline through Day 365 | |
Secondary | Evaluate the safety and tolerability of TOUR006 in participants with elevated cardiovascular risk and CKD | Evaluates the percentage of participants with treatment emergent adverse events and serious adverse events | 365 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06386172 -
Electronic Decision-support System to Improve Detection and Care of Patients With Chronic Kidney Disease in Stockholm
|
N/A | |
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT03434145 -
Changes of Ocular Structures After Hemodialysis in Patients With Chronic Kidney Diseases
|
N/A | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
Terminated |
NCT05022329 -
COVID-19 Vaccine Boosters in Patients With CKD
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04925661 -
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
|
Phase 1 | |
Recruiting |
NCT04961164 -
Resistant Starch Prebiotic Effects in Chronic Kidney Disease
|
N/A | |
Completed |
NCT05015647 -
Low Protein Diet in CKD Patients at Risk of Malnutrition
|
N/A | |
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Recruiting |
NCT06094231 -
Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study
|
N/A | |
Completed |
NCT04363554 -
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Recruiting |
NCT04831021 -
Pre- or Per-dialytic Physical Exercise : a Cardioprotective Role?
|
N/A | |
Terminated |
NCT04877847 -
Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury
|
N/A | |
Recruiting |
NCT04422652 -
Combination of Novel Therapies for CKD Comorbid Depression
|
Phase 2 | |
Completed |
NCT05055362 -
Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study
|
N/A | |
Not yet recruiting |
NCT06330480 -
Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease
|
N/A | |
Recruiting |
NCT03176862 -
Left Ventricular Fibrosis in Chronic Kidney Disease
|
N/A | |
Terminated |
NCT02539680 -
Intestinal Phosphate Transporter Expression in CKD Patients
|
N/A |